Verismo Therapeutics to Present First-in-Human KIR-CAR Clinical Data at ASH
Interim data for the CD19-targeted KIR-CAR T therapy showed no CRS or ICANS, according to the supplied body.
Interim data for the CD19-targeted KIR-CAR T therapy showed no CRS or ICANS, according to the supplied body.